The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings

Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver

(2011) B. Mukhopadhyay et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the Cannabinoid Pathway Limits the Development of Fibrosis and Autoimmunity in a Mouse Model of Systemic Sclerosis

(2010) Amélie Servettaz et al.   AMERICAN JOURNAL OF PATHOLOGY

A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents

(2010) NL Cluny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabinoid CB2 Receptors in Health and Disease

(2010) K. Patel et al.   CURRENT MEDICINAL CHEMISTRY

CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice

(2010) T. Jourdan et al.   DIABETES

Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age

(2010) J. Agudo et al.   DIABETOLOGIA

Endocannabinoids and Their Role in Fatty Liver Disease

(2010) A. Mallat et al.   DIGESTIVE DISEASES

Splanchnic Balance of Free Fatty Acids, Endocannabinoids, and Lipids in Subjects With Nonalcoholic Fatty Liver Disease

(2010) Jukka Westerbacka et al.   GASTROENTEROLOGY

Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration

(2010) Fatima Teixeira-Clerc et al.   HEPATOLOGY

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

(2010) Herbert Tilg et al.   HEPATOLOGY

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

(2010) Joseph Tam et al.   JOURNAL OF CLINICAL INVESTIGATION

791 BENEFICIAL EFFECTS OF CANNABINOID RECEPTOR 2 ON ALCOHOLIC LIVER DISEASE

(2010) A. Louvet et al.   JOURNAL OF HEPATOLOGY

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2

(2010) R. G. Pertwee et al.   PHARMACOLOGICAL REVIEWS

Hepatitis C Virus Induces the Cannabinoid Receptor 1

(2010) David van der Poorten et al.   PLoS One

Cannabinoid receptors as therapeutic targets in the management of liver diseases

(2009) A. Mallat et al.   DRUG NEWS & PERSPECTIVES

The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy

(2009) Nicole Defer et al.   FASEB JOURNAL

Cannabinoid Type 1 Receptor Antagonism Delays Ascites Formation in Rats With Cirrhosis

(2009) Marco Domenicali et al.   GASTROENTEROLOGY

Signalling pathways in alcohol-induced liver inflammation

(2009) Pranoti Mandrekar et al.   JOURNAL OF HEPATOLOGY

Alcoholic Hepatitis

(2009) Michael R. Lucey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis

(2009) Vanessa Deveaux et al.   PLoS One

Cannabinoids and Capsaicin Improve Liver Function Following Thioacetamide-Induced Acute Injury in Mice

(2008) Yosefa Avraham et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Prevention of Hepatic Fibrosis in a Murine Model of Metabolic Syndrome with Nonalcoholic Steatohepatitis

(2008) Laurie D. DeLeve et al.   AMERICAN JOURNAL OF PATHOLOGY

Paracrine Activation of Hepatic CB1 Receptors by Stellate Cell-Derived Endocannabinoids Mediates Alcoholic Fatty Liver

(2008) Won-il Jeong et al.   Cell Metabolism

Influence of Cannabis Use on Severity of Hepatitis C Disease

(2008) Julie H. Ishida et al.   Clinical Gastroenterology and Hepatology

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †

(2008) Luc F. Van Gaal et al.   EUROPEAN HEART JOURNAL

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

(2008) Catherine Postic et al.   JOURNAL OF CLINICAL INVESTIGATION

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

(2008) Douglas Osei-Hyiaman et al.   JOURNAL OF CLINICAL INVESTIGATION

Attenuation of Experimental Autoimmune Hepatitis by Exogenous and Endogenous Cannabinoids: Involvement of Regulatory T Cells

(2008) V. L. Hegde et al.   MOLECULAR PHARMACOLOGY

Targeting the endocannabinoid system: to enhance or reduce?

(2008) Vincenzo Di Marzo   NATURE REVIEWS DRUG DISCOVERY

Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?

(2008) George Kunos et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Endocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver

(2007) A. Mallat et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

CB2 receptors as new therapeutic targets for liver diseases

(2007) S Lotersztajn et al.   BRITISH JOURNAL OF PHARMACOLOGY

Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C

(2007) Christophe Hézode et al.   GASTROENTEROLOGY